Loading company…
VIMA Therapeutics develops treatments for dystonia and related movement disorders.
Founded by CEO Bernard Ravina and based in Cambridge, US, VIMA Therapeutics is developing an oral medication for dystonia. In March 2026, it raised USD 40 million in Series A funding from Frazier Healthcare Partners, Atlas Venture, Canaan Partners and Access Industries; the round was part of a larger USD 100 million Series A.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in